Correction: Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making (BMC Cancer, (2023), 23, 1, (689), 10.1186/s12885-023-11078-9)
BMC Cancer, ISSN: 1471-2407, Vol: 23, Issue: 1, Page: 768
2023
- 119Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Correction Description
Following publication of the original article [1], the authors reported that Figs. 4 and 5 were erroneously transposed. The original article [1] has been corrected. A Expression of cardiac marker cardiac troponin (green-cTnT) in iPSCs-derived cardiomyocytes with nucleus (blue) was observed. Flowcytometry analysis showed more than 80% expression of cardiac troponin in iPSCs-derived Cardiomyocytes. B Representative calcium-flux signal traces (average fluorescence intensities) for cardiotoxic compound-Doxorubicin. Traces shown are typical phenotypic responses including unaffected regular Ca flux patterns, and affected doxorubicin treated iPSC-derived cardiomyocytes (Control, Ovarian cancer and Breast cancer) patterns, Scale bar: 100 μm. C Representative calcium-flux signal traces (average fluorescence intensities) for chemotherapeutic cardiotoxic drugs. Traces shown are typical phenotypic responses including untreated regular Ca flux patterns, and treated doxorubicin patterns A Expression of glycogen storage (pink) and hepatic marker Albumin (green) in iPSCs-derived hepatocytes with nucleus (blue) was observed. Flowcytometry analysis showed more than 80% expression of Albumin in iPSCs-derived Hepatocytes. iPSC-derived hepatocytes (control, breast cancer and ovarian cancer patients) treated with Latrunculin showed sensitivity, Ovarian cancer and breast cancer hepatocytes showed more sensitivity than control. B Expression of endothelial marker CD31 (red-PECAM-1) in iPSCs-derived endothelial cells with nucleus (blue) was observed. Flowcytometry analysis showed more than 80% expression of CD31 in iPSCs-derived endothelial cells. Montage Image of in vitro angiogenesis assay on Matrigel revealed the potential to form capillary tubular networks of iPSC-ECs. Scale bar: 100 μm
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know